Lazard Asset Management
NVCR icon

Lazard Asset Management’s NovoCure NVCR Stock Holding History

Lazard Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,115
Closed -$131K – 1989
2025
Q3 		$131K Sell
10,115
-80,182
-89% -$1.07M ﹤0.01% 1655
2025
Q2 		$1.61M Buy
90,297
+87,021
+2,656% +$1.52M ﹤0.01% 1089
2025
Q1 		$58K Sell
3,276
-485
-13% -$11K ﹤0.01% 1963
2024
Q4 		$112K Sell
3,761
-22
-0.6% -$466 ﹤0.01% 1771
2024
Q3 		$59K Buy
3,783
+3,764
+19,811% +$68.3K ﹤0.01% 1888
2024
Q2 		$0 Hold
19
– – ﹤0.01% 2370
2024
Q1 		$0 Hold
19
– – ﹤0.01% 2270
2023
Q4 		$0 Hold
19
– – ﹤0.01% 2396
2023
Q3 		$0 Hold
19
– – ﹤0.01% 2414
2023
Q2 		$0 Sell
19
-1,027
-98% -$63.8K ﹤0.01% 2466
2023
Q1 		$62K Hold
1,046
– – ﹤0.01% 1729
2022
Q4 		$76K Hold
1,046
– – ﹤0.01% 1629
2022
Q3 		$79K Buy
1,046
+1,038
+12,975% +$81K ﹤0.01% 1583
2022
Q2 		$0 Sell
8
-1,342
-99% -$101K ﹤0.01% 2509
2022
Q1 		$111K Buy
1,350
+843
+166% +$62.1K ﹤0.01% 1367
2021
Q4 		$38K Sell
507
-14,659
-97% -$1.47M ﹤0.01% 1853
2021
Q3 		$1.76M Buy
15,166
+14,440
+1,989% +$2.18M ﹤0.01% 937
2021
Q2 		$161K Sell
726
-112
-13% -$21.8K ﹤0.01% 1244
2021
Q1 		$110K Sell
838
-132
-14% -$20.9K ﹤0.01% 1190
2020
Q4 		$167K Sell
970
-877
-47% -$120K ﹤0.01% 1121
2020
Q3 		$205K Sell
1,847
-323
-15% -$25.8K ﹤0.01% 965
2020
Q2 		$128K Sell
2,170
-502
-19% -$33K ﹤0.01% 971
2020
Q1 		$179K Buy
2,672
+2,079
+351% +$164K ﹤0.01% 914
2019
Q4 		$49K Hold
593
– – ﹤0.01% 1064
2019
Q3 		$44K Buy
+593
New +$47.4K ﹤0.01% 1009
2018
Q1 		– Sell
-13,425
Closed -$271K – 1090
2017
Q4 		$271K Buy
+13,425
New +$259K ﹤0.01% 851

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Lazard Asset Management's NVCR Position: Q4 2025 in Review

Lazard Asset Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 10,115 shares — an estimated $131K sold.

Lazard Asset Management first reported a position in NVCR in Q4 2017 and held it in 26 quarters. The position peaked at $1.76M in Q3 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Lazard Asset Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Lazard Asset Management sold 10,115 NovoCure shares in Q4 2025, an estimated $131K.
  • Lazard Asset Management first reported a position in NovoCure in Q4 2017 and held it in 26 quarters.
  • Lazard Asset Management's NovoCure position peaked at $1.76M in Q3 2021.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.